First-in-human global multi-center study of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer.

Authors

Cesar Augusto Perez

Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL

Cesar Augusto Perez , Jason Timothy Henry , Andreas Varkaris , Vivek Subbiah , Alexander I. Spira , Oleg Schmidt , Jinshan Shen , Wei Guo , Tamieka Hunter , Kai Yu Jen , Mahesh Padval , Djuro Karanovic , Beni B. Wolf , Erika P. Hamilton

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.

First Author: Cristina Saura

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL).

First Author: Dejan Juric

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).

First Author: Dejan Juric

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).

First Author: Dejan Juric